Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Company facts
| Company | Abbott Laboratories |
|---|---|
| Symbol | ABT |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market cap | $178.85B (Massive market data, 2026-09-10) |
| Employees | 115,000 |
| Country | United States |
| Website | https://www.abbott.com |
Trading — Abbott Laboratories
| Last price | $101.95 |
|---|---|
| Change | -1.36% |
| Previous close | $103.36 |
| Day range | $101.49 – $104.18 |
| 50-day average | $104.85 |
| 200-day average | $106.08 |
| Average volume | 9,825,328 |
Price basis: 2026-09-11T20:59:23.820251+00:00
Valuation and financial health
| Earnings per share | $3.14 |
|---|---|
| Price / book | 3.50 |
| Price / cash flow | 18.06 |
| Enterprise value / EBITDA | 19.12 |
| Enterprise value / sales | 4.43 |
| Debt / equity | 0.64 |
| Current ratio | 1.38 |
| Dividend yield | 2.38% |
| Free cash flow | $7.82B |
| Cash ratio | 0.29 |
| Enterprise value | $206.36B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-21 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $1.43 |
| Year-ago EPS | $1.30 |
| Analyst estimates | 8 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABT are on the IntelTrends dashboard.